This post was originally published on this site
The panel will discuss authorizing Pfizer Inc (NYSE:PFE)’s COVID-19 vaccine for children aged five through 11 on Oct. 26, the FDA said on Friday.
Last month, the FDA authorized https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-authorize-third-dose-pfizer-covid-19-vaccine-older-americans-bloomberg-2021-09-22 a booster dose of the Pfizer and BioNTech vaccine for older adults and some Americans at high-risk of illness.
Roughly 4 million Americans have received a booster dose as of Thursday, according to data from the Centers for Disease Control and Prevention.
The panel, called the Vaccines and Related Biological Products Advisory Committee, will hold a meeting on Oct. 14 to discuss a booster dose of the Moderna vaccine, and discuss J&J’s boosters on Oct. 15.
The panel will also review data on receiving a booster dose of a different vaccine than the one used in the original vaccine series.
